5.2: POLICY FOR THE MANAGEMENT OF INDIVIDUAL PATIENT TREATMENT REQUESTS

PURPOSE OF PAPER

This policy outlines the NHS GG&C management process of Individual Patient Treatment Requests (IPTRs) for medicines being used within their licensed indications when:

- The SMC or NHS HIS has yet to issue advice on the medicine
- The SMC or NHS HIS has issued “not recommended” advice for the medicine, including medicines not recommended by SMC due to company non-submission
- The request relates to the use of the medicine outwith an SMC restriction

Where no SMC/NHS HIS advice is yet available but is awaited, the policy position in NHS GG&C is that a medicine is not expected to be routinely prescribed. However an IPTR may be considered in this timeframe where the clinician responsible for the patient believes a delay in treatment pending SMC/NHS HIS advice would result in a significant adverse outcome for the patient.

This policy also incorporates guidance intended to introduce ‘flexibility’ into the IPTR process as outlined in Access to Medicines – Transitional arrangements for processing individual patient treatment requests (SGHD/CMO(2013)20)

BACKGROUND

The Individual Patient Treatment Request (IPTR) process was introduced in 2010 to reflect guidance from Scottish Government (CEL (2010)17 and CMO (2011)3) regarding the introduction and availability of newly licensed medicines. In November 2013, following on from the New Medicines Review and additional guidance from Scottish Government (SGHD/CMO(2013)20), a replacement process (Peer Approval Clinical System (PACS)) was proposed.

To provide clinicians with additional guidance on the management of IPTRs and the introduction of additional ‘flexibility’, an interim policy statement was published by NHS GG&C. The guidance from that interim policy has now been incorporated into this revised policy.

OVERVIEW OF IPTR AND NON-FORMULARY PROCESS IN THE ACUTE SECTOR

The IPTR policy is applicable to all directly provided NHS GG&C services and its intention is to ensure a fair and consistent approach for all patients referred to NHS GG&C clinicians for treatment regardless of originating Health Board.

There are three levels of non-Formulary medicines, and the required actions vary between them. Level 1 medicines are typically those that pre-date SMC or NHS HIS advice or are usually prescribed at low levels at low cost and are outwith the remit of the IPTR process. Level 1 medicines require no documentation to be completed prior to prescribing. Level 2 and Level 3 medicines require the completion of an IPTR and both share the same principles in terms of referral criteria and additional flexibility. However, the process for each of them differs in terms of documentation and who approves the request as outlined below.

A short list of medicines, predominantly those likely to be prescribed and/or continued in primary care which are not recommended for use by the SMC or NHS HIS is produced locally (known as the IPTR List). This list details medicines that are designated as level 2 or level 3 from specialties other than Oncology and Haemato-oncology. The IPTR List can be accessed via the Non-Formulary information page of the GGC Medicines website (click here).

a. LEVEL 2 IPTRS
For medicines or indications on this list designated as level 2, Form IPTR 2 will need to be completed by the prescriber, the nurse in charge of the ward or pharmacy staff when a supply is required to be made by pharmacy.

Where the medicine is being newly initiated, this request will be required to be considered by the relevant Clinical Director or Chief of Medicine in accordance with the criteria outlined in this policy document for level 3 IPTRs.

Where the medicine is a continuation of existing treatment upon admission to hospital, a form will be required to be completed, but does not require approval prior to supply.

Where a non-Formulary medicine has been prescribed but a supply is not being made (for example, when the patient has their own supply of the medicine), there is no need to complete a form.

b. LEVEL 3 IPTRS

Those medicines or indications which are not recommended for use by SMC or NHS HIS or are awaiting evaluation and where there are substantial implications associated with prescribing, which may require subsequent financial and service management are designated as level 3. Generally, these medicines are specialist in nature with a cost per patient treatment in excess of £3,000 (or £3,000 per patient per annum for continuing treatment).

These medicines or indications require the completion of an Individual Patient Treatment Request (Form IPTR 3) by the requesting consultant and will require approval by an IPTR Directorate Panel prior to a supply being made.

REQUESTS FOR MEDICINES NOT INCLUDED IN THE IPTR LIST

Though the IPTR List is updated regularly, not all situations where the completion of an IPTR is required can be shown on this list. This includes medicines that may have been recently licensed and/or considered by SMC since the IPTR List was last updated.

In circumstances where there is uncertainty, the Formulary & Therapeutic Handbook Team should be approached for specific advice (contact the team on (0141) 211 4407 or via the Medicines Information email address: ggc.medicines@ggc.scot.nhs.uk).

PROCESS FOR REVIEWING LEVEL 3 IPTRS

The process for reviewing a Level 3 IPTR for a medicine, indication or formulation that is not recommended for use or awaiting evaluation by the Scottish Medicines Consortium (SMC) or NHS HIS is detailed below. The aim is to ensure a consistent approach for all patients throughout the health board in accordance with guidance from The Scottish Government (as detailed in CEL(2010)17, CMO(2011)3) and more recently in CMO(2013)20.

1. PANEL MEMBERSHIP

The Panel for reviewing a request for an Individual Patient Treatment Request (IPTR) will typically consist of:

- The Chief of Medicine for the relevant sector (or nominated deputy)
- The General Manager for the relevant directorate (or nominated deputy)
- Senior pharmacist
- Senior medical representative, with specialist knowledge of the medicine / condition

All participants will complete a Declarations of Interest form for the record.

In some circumstances it may be appropriate for Panel discussion and decision-making to be conducted remotely without the need to meet, however in all cases relevant interests should be declared and recorded.

The roles of the Panel members will differ in relation to their position:

- The Chief of Medicine (CoM) will act as chair and will consider the views of the other Panel members before seeking (typically) a consensual decision or (rarely) a majority decision on the request. Should there be a split decision, then the CoM has the casting vote
The General Manager has a role to specifically consider the service issues of the request including consideration for the current and future implications on the budget and service. The role of the specialist medical adviser is described in 5.2.2. He/she will inform the Panel from the perspective of his/her clinical experience with the medicine / condition.

The senior pharmacist will facilitate an overview of the clinical evidence and ensure alignment with due process (see 5.2.3 Briefing Notes for Lead Clinical Pharmacists Supporting IPTR Panels)

2. SUPPORT FOR IPTR PANELS
A Specialist Advisor (usually a specialist clinician) will be required to support the IPTR Panel and will primarily contribute a clinical perspective on the merits of the application (see 5.2.2 Briefing Notes for Specialist Advisors Supporting IPTR Panels)

3. REFERRAL CRITERIA AND CONSIDERATIONS BY THE IPTR PANEL
An IPTR can only be submitted when the clinician fully supports the request. The referral criteria for an IPTR should relate to the clinical circumstances (condition and characteristics) of an individual patient.

Cases referred to the IPTR Panel should seek to demonstrate the following criteria:

- That the patient’s clinical circumstances (condition and characteristics) are significantly different from either:
  - The general population of patients covered by the medicine’s licence (for medicines awaiting evaluation or non-submissions to SMC); or
  - The population of patients included in the clinical trials for the medicine’s licensed indication as appraised by the SMC or NHS HIS

AND

- That these circumstances imply that the patient is likely to gain significantly more benefit from the medicine than would normally be expected.

These are clinical criteria which are assessed on a case by case basis. Affordability or cost is not considered as part of the assessment.

In relation to more recent advice from Scottish Government (CMO(2013)20), the panel will exercise additional flexibility via:

- The expectation that peer review will be incorporated as part of the evidence base e.g. an MDT report or the opinion of the Clinical Team Lead
- The option for the IPTR applicant (clinician) to contribute directly to the panel discussion
- The additional emphasis on ‘peer approval’ where the evidence is equivocal, where the panel decision is split or where reasonable doubt exists for rejection of the IPTR referral criteria.

Where SMC/NHS HIS advice is not yet available and therefore there is no clinical and cost effectiveness assessment, the policy position in NHS GG&C is that the medicine should not be prescribed. Where the IPTR has been initiated in this circumstance the Panel should consider whether there is an alternative treatment available and whether a delay in treatment pending SMC/NHS HIS advice would result in significant adverse outcome for the patient.

4. COMMUNICATION WITH THE PATIENT
(Also see section 5.2.1 Briefing Notes for Consultants submitting an IPTR)

The patient is supported and guided through the IPTR process primarily by his/her consultant, who will outline the terms on which an IPTR can be submitted and the basis of the case for the IPTR in addition to answering any specific questions the patient may have. The patient is also supported by other means including:

- Patient Information Leaflet: This outlines the IPTR process and appeals process in NHS GG&C in terms that can be easily comprehended by most patients and answers the most frequently asked questions (see 5.2.4 Patient Information Leaflet: Access to New Medicines in the NHS)
Access to other persons within the Health Board who can offer support regarding the IPTR process (via the patient’s consultant)

5. APPLICATION FOR PATIENTS RESIDING OUTWITH NHS GG&C

The West of Scotland Health Boards have agreement on the management of IPTRs within each others’ Boards. The host Board is the one to which the patient has been referred from a home Board. The host Board (in this case NHSGG&C) and the host Board’s Clinician assume responsibility for the patient’s care. Two separate mechanisms will be applied, dependent on the cost per patient treatment or cost per patient per annum for continuing treatment:

(a) < £25,000
The standard NHS GG&C procedures will apply, with notification of the decision to the Medical Director of the home Board (or nominee) at the conclusion of the Panel review

(b) ≥ £25,000
An invitation will be extended to the Medical Director of the home Board (or their nominee) to participate as a Panel Member with full voting rights.

The decision of NHS GG&C Panel will be final and not subject to a further review at home Board level.

Following receipt of a decision from an IPTR, the home Board has the opportunity of providing feedback to inform the process for future IPTR Panels.

Note: NHS Highland requires patients referred to NHS GG&C for treatment to submit any IPTR directly to NHS Highland for consideration. Details for the IPTR process in NHS Highland, including the documentation to be used, can be accessed via the NHS Highland website (www.nhshighland.scot.nhs.uk).

6. APPLICATION FOR PATIENTS REFERRED TO HEALTH BOARDS / TRUSTS OUTWITH NHS GG&C

In circumstances where a patient is referred to a clinician outwith NHS GG&C for advice, but the responsibility of prescribing remains with the local clinician, NHS GG&C Formulary processes will apply, including the completion of an IPTR application. This advice will form part of the evidence for consideration by the NHS GG&C Panel.

In circumstances where a patient is referred to a clinician outwith NHS GG&C for full clinical responsibility / supervision of care, then NHS GG&C will normally abide by the prescribing policies and decisions of the external Board / Trust, although completion of the NHS GG&C IPTR documentation is considered good practice for audit and financial control purposes.

7. TIMESCALE FOR DECISION

Timescales for the decision-making process will be established in accordance with the patient’s clinical needs and be communicated to the patient by the clinician responsible for the patient’s care, following discussion with those involved in dealing with the request. Upon receipt of an IPTR, in establishing an IPTR Panel, due consideration is given to the urgency of the request given the patient’s clinical condition. A date should be set to review the IPTR and examine the evidence and advise the patient of the date accordingly. The aim is for the timescale between the receipt of the IPTR and a decision not to exceed 20 working days.

There may be cases where an IPTR is considered an emergency and there is not sufficient time to fulfil the formal process. In these cases, the Chief of Medicine (or nominated deputy) will be required to make a rapid assessment about the appropriateness of the request and approve the use of the medicine on a short-term basis to allow time for the full approval process to be completed. It should be understood that a decision to approve an IPTR in these circumstances will not imply a commitment to further prescribing when a full application and evaluation takes place. In such cases, the AMD will be supported by senior medical and pharmacy colleagues as required.
8. NATURE OF EVIDENCE
The onus is on the applicant to demonstrate that the referral criteria described in Section 3 are fulfilled and clearly described in a fully completed IPTR3 Form. The evidence that the Panel considers may include:

- SMC/NHS HIS advice and the detailed advice document (DAD) where available
- The referral criteria
- The IPTR case report from the requesting clinician which will comprise:
  a. The rationale for the IPTR request including patient treatment history, prognosis and specific clinical characteristics
  b. Information on expected response and benefit
  c. Consequences of not using the treatment from both a patient and service perspective
  d. Consequences of using the treatment, including cost, duration of treatment and stopping rules
  e. Any other relevant information such as case reports and further evidence from literature reviews
- Patient /patient advocate statement
  If the patient is able and wishes, he / she can be given an opportunity to contribute to the evidence reviewed by the Panel by completing the appropriate section of the IPTR 3 form. This may be prepared by the patient or by a representative on his / her behalf. This will be presented in the knowledge that the IPTR decision will be based on clinical factors only and will take no account of the patient’s social circumstances. Formal consent will be sought in the event of involvement of a patient representative.
- The incorporation of peer review into the evidence base, e.g. an MDT report or the opinion of the Clinical Team Lead.
- Declarations of interests, both of the clinician supporting the IPTR and the IPTR Panel.

In most cases the evidence provided by the clinician will be supplemented by an independent evidence briefing prepared by an appropriate clinical / medicines information pharmacist for consideration by the Panel. A template is available for this purpose (appendix 1)

The completed IPTR3 Form together with any supporting literature should be submitted to the relevant CoM who will initiate the review and circulate to the other Panel Members.

All supporting evidence, including any patient statement, should be submitted to the IPTR Panel to allow sufficient time for it to be circulated and evaluated by Panel members prior to the Panel hearing. Unless there are exceptional circumstances, this should be at least 3 working days prior to the Panel hearing. Flexibility on this timescale applies to patient statements in support of an IPTR, but these should not be submitted within 48 hours of the Panel hearing.

9. PRIVATE HEALTHCARE
Where a patient has used private treatment to access a medicine not routinely available in NHS Scotland, they are not expected to be eligible to apply for that medicine to be funded by the NHS via an IPTR during that episode of care. If an IPTR is being pursued, evidence from experience in the private sector can be submitted to support the application if it is an objective and scientific measurement of response. However, a demonstrable response is not necessarily an indicator that a patient will meet the criteria required for IPTR acceptance. This is in keeping with the principles laid down in the guidance to the NHS in Scotland and helps avoid the development of inequity in access to NHS services.

10. PANEL DECISION
The Panel will weigh up the evidence for the application in order to make their decision, considering the applicability of the referral criteria and additional flexibility as outlined in Section 3. Where the request for the medicine is likely to impact on more than one directorate, it will be the responsibility of the Panel to liaise with other directorates as appropriate.
11. DOCUMENTATION AND COMMUNICATION OF DECISION

The decision of the Panel, along with any relevant supporting information or terms of use, will be recorded in full by the Panel on the relevant section of Form IPTR3. It is essential that any decision is documented carefully. This information should include a clear explanation and justification of the decision, dates of any meetings and full details of all those involved.

On reaching a decision, a written note of the IPTR outcome and a copy of the fully completed Form IPTR3 will be provided to the requesting clinician, by the IPTR Panel Chair. This will provide a brief summary of the rationale for the decision.

The requesting clinician will then have the responsibility to communicate this decision to the patient or patient’s representative. If positive, then the medicine can be prescribed on the NHS with immediate effect, dependent on the individual circumstances of the case. If negative, when discussing this outcome for the IPTR, the clinician should also clarify the options open to the patient for future treatment including the possibility of an appeal if there are grounds for this. The option to appeal (Section 5.3) is available to the clinician, in consultation with the patient, within 2 months of the IPTR decision.

A copy of the completed Form IPTR3, regardless of the outcome of the review, should be sent to the Lead Pharmacist for Formulary and Prescribing Interface. The AMD should retain a copy of all documents for their own records, which may help in the evaluation of future requests for the same medicine.

Data from the IPTR documentation will then be collated in a secure database complying with Scottish Government advice.

12. IPTR APPEAL

A consultant has the right to ask for a review of the process or decision applied to an IPTR declined at sector level (or in the case haemato-oncology, oncology or neurology at service level) (Section 5.3). Each appeal must be supported by relevant documentation. It is the aim that the appeal will be heard within 20 working days of submission, by a Review Panel of the Board Medical Director, the Head of the Pharmacy & Prescribing Support Unit (PPSU) or their nominees, a lay member, supported by a specialist advisor (if required). Their decision will be final. The Panel will be supported by the PMG Professional Secretariat (or nominee) as described in NHS GG&C ‘Policies relating to management of medicines’, Section 5.3 Individual Patient Treatment Request Appeal Process.

13. REAPPLICATION THROUGH IPTR PROCESS

Should an IPTR and a subsequent IPTR Appeal be rejected, the options remaining to the patient, including the potential procurement of the requested medicine via a co-payment agreement (see 5.5 Policy for Patients to Receive Aspects of Their Treatment Through Private Healthcare Providers (Co-payments)) will be outlined by the patient’s clinician.

If the medicine/indication/formulation subsequently becomes accepted for use within NHS Scotland through SMC or HIS, the individual case and appropriateness of the treatment will be re-evaluated by the patient’s clinician.

Should new clinical evidence emerge for an individual case or there is a material change in the patient’s condition that may impact on the outcome of the IPTR, application of a new IPTR at directorate level may be considered where the clinician is in support.
### Individual Patient Treatment Request (IPTR) Evidence Briefing

<table>
<thead>
<tr>
<th>Name of Medicine</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Licensed Indication</td>
<td></td>
</tr>
<tr>
<td>Indication under review</td>
<td></td>
</tr>
<tr>
<td>SMC Status</td>
<td><a href="http://www.scottishmedicines.org.uk/Home">http://www.scottishmedicines.org.uk/Home</a></td>
</tr>
<tr>
<td>Other relevant national Advice</td>
<td></td>
</tr>
<tr>
<td>National Institute for Health and Clinical excellence (NICE)</td>
<td><a href="http://www.nice.org.uk/Guidance/TA/Published">http://www.nice.org.uk/Guidance/TA/Published</a></td>
</tr>
<tr>
<td>SIGN Guidelines</td>
<td><a href="http://www.sign.ac.uk/">http://www.sign.ac.uk/</a></td>
</tr>
<tr>
<td>Other professional guidelines</td>
<td></td>
</tr>
<tr>
<td>Dose and Administration</td>
<td></td>
</tr>
<tr>
<td>Background</td>
<td></td>
</tr>
<tr>
<td>Summary of evidence of comparative efficacy and adverse effects</td>
<td></td>
</tr>
<tr>
<td>Clinical Effectiveness</td>
<td></td>
</tr>
<tr>
<td>Health Economics</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td></td>
</tr>
<tr>
<td>Author’s details</td>
<td></td>
</tr>
<tr>
<td>Written by:</td>
<td></td>
</tr>
<tr>
<td>Reviewed by:</td>
<td></td>
</tr>
</tbody>
</table>